Yinuo Pharmaceutical: The clinical trial of Isumaglutide for the treatment of adolescent obesity has been approved.

On June 22nd, at noon, Yinuo Pharmaceuticals announced on the Hong Kong Stock Exchange that on June 17th, 2026, the group had received approval from the National Medical Products Administration of the People's Republic of China to conduct Phase 1b clinical trials for the use of Sufghanolide in treating adolescent obesity. The company expects the clinical trial to begin in July 2026 and plans to recruit approximately 36 participants for the trial.